Versions Compared

Key

  • This line was added.
  • This line was removed.
  • Formatting was changed.

...

Disease

Autosomal dominant intellectual disability

Inheritance

autosomal dominant

Prevalence

Expand
titlePossible sources

Orphanet

Medline Plus Genetics

Common or non-specific

Source:

Rapid or full curation?

  •  Rapid
  •  Full

ClinGen / GenCC / BabySeq / HGMD / OMIM

ClinGen has a curation for AD distal hereditary motor neuronopathy (https://search.clinicalgenome.org/kb/genes/HGNC:2961), as well as dosage sensitivity curations. ClinGen dosage sensitivity curations indicate no evidence for triplosensitivity or haploinsufficiency. From ClinGen’s dosage sensitivity curation: “Variants in the N-terminal stem domain are more commonly described in patients with autosomal dominant neuromuscular disease (e.g. autosomal dominant axoxinal Charcot-Marie-Tooth disease type 2O, lower extremity-predominant spinal muscular atrophy-1), whereas variants in the C-terminal motor domain are more commonly reported in patients with intellectual disability (ID) and malformations in cortical development (MCD)”.

Not in BabySeq.

GenCC:

  • 3 submissions for autosomal dominant childhood-onset proximal spinal muscular atrophy without contractures (definitive, strong, supportive).

  • 1 submission for autosomal dominant non-syndromic intellectual disability (supportive).

  • 2 submissions for Charcot-Marie-Tooth disease axonal type 2O (strong, supportive).

  • 3 submissions for intellectual disability, autosomal dominant 13 (definitive, strong, strong).

  • 1 submission for distal hereditary motor neuronopathy (definitive by ClinGen).

OMIM:

  • AD Charcot-Marie-Tooth disease, axonal, type 2O

  • AD Cortical dysplasia, complex, with other brain malformations 13

  • AD Spinal muscular atrophy, lower extremity-predominant 1

Clinical Validity Scoring Notes and points

Variant/Case Evidence :(7 points)

  • DYNC1H1 p.del659-662 - 0.6 points

    • Not in GnomAD v4.

    • PMID: 23603762, Patient P144, 15yo with microcephaly, bedridden, spastic tetraplegia, early onset epilepsy, MRI findings. De novo. Variant identified through targeted screening of DYNC1H1, TUBG1, KIF2A, and KIF5C (Supp Table 4)

  • DYNC1H1 p.K129I - 0.6 points

    • Not in GnomAD v4.

    • REVEL = 0.390.

    • PMID: 23603762, Patient P582, 10yo with severe ID, late onset epilepsy, MRI findings. De novo. Variant identified through targeted screening of DYNC1H1, TUBG1, KIF2A, and KIF5C (Supp Table 4).

  • DYNC1H1 p.K3336N - 1.1 points

    • Not in GnomAD v4.

    • REVEL = 0.540.

    • PMID: 23603762, Patient P122, 12yo with microcephaly, bedridden, spastic tetraplegia, early onset epilepsy, foot deformities, MRI findings. De novo. Variant identified on exome. (Supp Table 4). Functional studies and showed that this variant showed a significant reduction in microtubule binding affinity compared to WT control (Fig 3d).

  • DYNC1H1 p.R3384Q- 1.1 points

    • Not in GnomAD v4.

    • REVEL = 0.395

    • PMID: 23603762, Patient P217, 10yo with microcephaly, bedridden, spastic tetraplegia, early onset epilepsy, foot deformities, MRI findings. De novo. Variant identified on exome. (Supp Table 4). Functional studies and showed that this variant showed a significant reduction in microtubule binding affinity compared to WT control (Fig 3d).

  • DYNC1H1 p.R1567Q- 0.6 points

    • Not in GnomAD v4.

    • REVEL = 0.508

    • PMID: 23603762, Patient P398, 7yo with severe ID, no epilepsy and normocephalic, foot deformities, MRI findings. De novo. Variant identified on exome. (Supp Table 4).

  • DYNC1H1 p.R3344Q- 1.2 points

    • Not in GnomAD v4.

    • REVEL = 0.439

    • PMID: 23603762, Patient P535, 5yo with severe ID and autistic features, Lennox Gastaut and normocephaly, MRI findings, De novo. Variant identified through targeted screening of DYNC1H1, TUBG1, KIF2A, and KIF5C (Supp Table 4).

    • PMID: 23603762, Patient 574C, 3 yo with moderate ID and focal seizures, MRI findings. De novo. Variant identified through targeted screening of DYNC1H1, TUBG1, KIF2A, and KIF5C (Supp Table 4).

  • DYNC1H1 p.R1962C - 0.6 points

    • Not in GnomAD v4.

    • REVEL = 0.441

    • PMID: 23603762, Patient 360J, 19yo with severe ID and focal seizures, MRI findings. De novo. Variant identified through targeted screening of DYNC1H1, TUBG1, KIF2A, and KIF5C (Supp Table 4).

    DYNC1H1 p.K3241T

    • Not in GnomAD v4.

    • REVEL = 0.568

    • PMID: 23603762, Patient 346D, 11yo with focal seizures and MRI findings. Variant was inherited from mother who had focal epilepsy (less severely affected). MRI findings. Brother also carried the variant and was affected (8yo, focal seizures, mild ID, MRI findings). (see Supp table 4 and supp fig 5).

  • DYNC1H1 p.Glu1518Lys - 0.6 points

    • Not in GnomAD v4.

    • REVEL = 0.573

    • PMID: 22368300 - 51yo female with severe ID (never been able to walk or speak), congenital clubfeet, epileptic seizures, short stature, head circumference in 2nd percentile. dysmorphic features. wide lateral and third ventricles on CT scan. De novo p.Glu1518Lys variant identified on trio exome sequencing. Non-paternity and sample mixup were excluded.

  • DYNC1H1 p.His3822Pro - 0.6 points

    • Not in GnomAD v4.

    • REVEL = 0.718

    • PMID: 22368300 - male with hypotonia, developmental delay, moderately severe ID, mild dysmorphic features. His3822Pro variant was found on trio exome sequencing, de novo. Non-paternity and sample mixup were excluded.

    • PMID: 21076407 - same case as above. PMID 21076407 is the original report.

Segregation Evidence:

  • DYNC1H1 p.K3241T - I think this was discovered using a targeted panel, so not counting segregations in this family.

    • Not in GnomAD v4.

    • REVEL = 0.568

    • PMID: 23603762, Patient 346D, 11yo with focal seizures and MRI findings. Variant was inherited from mother who had focal epilepsy (less severely affected). MRI findings. Brother also carried the variant and was affected (8yo, focal seizures, mild ID, MRI findings). (see Supp table 4 and supp fig 5).

Case/Control Evidence:

Experimental Evidence:

SourceOther papers not yet reviewed: 23603762 26395554 28196890 29243232P122 and P398, Table 1, Supplementary Table 4 and Fig. 3, 34803881, 32788638 (likely many others).

Clinical Validity Points Total

7 points so far (incomplete)

Source:

Clinical Validity Classification

Expand
titleClassifications (pts)

Definitive (12pts)

Strong (12pts)

Moderate (7-11pts)

Limited (0.1-6pts)

No genetic evidence

Refuted

Disputed

Source:

Molecular Mechanism

Expand
titleMechanisms

Loss of function

Gain of function

Dominant negative

Unknown

Other

Loss of function / Gain of function / Dominant Negative

Penetrance

Expand
titleoptions

Complete (100%)

High (≥80%)

Moderate  (<80% and >20%)

Low (≤20%)

(list source/PMID)

Source:

Age of Onset

Expand
titleoptions

Congenital

Pediatric

Adolescent

Adulthood

Late adulthood

(list source/PMID)

Severity

Expand
titleOptions

Embryonic lethal - presence of a pathogenic variant or variants is not compatible with life. The penetrance must be complete.
Severe - presence of a pathogenic variant or variant(s) results in significantly reduced fitness. The penetrance must be complete or high.
Moderate - significant morbidity or mortality due to clinical features, but fitness may not be reduced, or penetrance is reduced.
Mild - Presence of a variant or variant(s) is not associated with reduced fitness, no significant morbidity or mortality, and/or penetrance is low.
None - presence of a variant results in no phenotype. An example is recessive disorders in which no phenotype is reported in carriers.

Clinical Features

Sources:

HPO Terms

https://hpo.jax.org/app/

Gene SOPs & Notes

 LINK if SOP is a long document. Short notes if it is easy to digest. eg. Last known truncating variant

Curation Summary

Expand
titleExamples

- The @GENE@ is associated with @inheritance pattern@ @condition@, which is characterized by @clinical features@ (PMIDs).

- Variable expression or severity:
The severity and expressivity of the disorder is highly variable, even within families.
- If multiple conditions associated with the gene:
It has also been associated with @inheritance pattern@ @condition@, which is characterized by @clinical features@ (PMIDs).

- Limited evidence gene: The PCNA gene has been reported in individuals with early onset autosomal recessive ataxia (PMID: 33426167, 24911150), however, evidence supporting this gene-dIsease relationship is limited

The DYNC1H1 gene is associated with autosomal dominant syndromic intellectual disability. It is primarily caused by de novo missense variants, although some familial cases and other variant types have been reported (PMID: 22368300, 23603762, 34803881). The clinical characteristics are variable. Affected individuals may present with infantile spasms, epileptic encephalopathy, microcephaly, dysmorphic features, intellectual disability, or developmental delay. The DYNC1H1 gene has also been shown to be associated with distal hereditary motor neuropathy, and some individuals have features that overlap between the two conditions (PMID: 32656949, 32788638).

Case ID, Curator name, Date, Jira ticket link

D-141007478-BH-4001-P-A, Areesha Salman, 2/18/24